Sales & Marketing Sponsored Pushing through barriers to commercial launch success, with ... In this sponsored pharmaphorum podcast, Amanjeet Singh Saluja, a Principal at Axtria, discusses the current state of affairs in launch success.
Sales & Marketing Execution drift: Why pharmaceutical go-to-market falls short... Execution drift occurs when strategy, targeting, metrics, incentives, and behaviour gradually stop reinforcing one another.
Digital Cracking the code: How European biotechs can win in the US m... At Frontiers Health 2025, Mike Ryan, General Manager Europe at EVERSANA, tackled one of the most pressing questions for emerging pharma and biotech...
Market Access How are the US MFN and German MFG likely to impact pharmaceu... A comparison of the US MFN and German MFG.
Sales & Marketing Unlocking pharma launch potential: Integrated data strategie... Launch teams need real-time, integrated intelligence to navigate tighter markets, faster timelines, and rising expectations.
Market Access Sponsored The stealth market access strategy that’s quietly making man... There is an under-the-radar market access strategy that some manufacturers have implemented, but many others remain unaware of.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.